STAQ Pharma of Ohio, LLC, Columbus, OH
Is STAQ Pharma of Ohio, LLC registered with the FDA as a 503B outsourcing facility?
Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names STAQ Pharma of Ohio, LLC in Columbus, OH, first registered Jan 26, 2023 and most recently registered Dec 18, 2025.
Does STAQ Pharma of Ohio, LLC hold a Ohio pharmacy license?
State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks. The California State Board of Pharmacy also lists nonresident license NSF 151 for Staq Pharma Of Ohio Llc, Columbus, OH, status Active, as of Nov 6, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0010095 for STAQ Pharma of Ohio, LLC, COLUMBUS, OH, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301013323 for STAQ Pharma of Ohio, LLC, Columbus, OH, status Active, as of Nov 10, 2026.
Has STAQ Pharma of Ohio, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Dec 5, 2025) and 2 FMD-145 letters (Mar 20, 2024 and Apr 9, 2026) for STAQ Pharma of Ohio, LLC. State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- STAQ Pharma of Ohio, LLC
- Location
- Columbus, OH
- Type as FDA labels it
- 503B
- FDA 503B list
- Listed as STAQ Pharma of Ohio, LLC
- Form 483s on FDA’s actions page
- 3
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Aug 19, 2026
- FDA Data Dashboard inspections
- 2 inspections: 2 VAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 8 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as STAQ Pharma of Ohio, LLC, a 503B facility, with 6 dated actions.
| Document | |||
|---|---|---|---|
| Aug 19, 2026 | Form 483 | 483 issued 08/19/2026 | fda.gov |
| Apr 9, 2026 | FMD-145 letter | FMD-145 Letter Issued 04/09/2026 | Not linked by FDA |
| Dec 5, 2025 | Untitled letter | Untitled Letter issued 12/05/2025 | fda.gov |
| May 16, 2025 | Form 483 | 483 Issued 05/16/2025 | fda.gov |
| Mar 20, 2024 | FMD-145 letter | FMD-145 Letter Issued 03/20/2024 | Not linked by FDA |
| Oct 4, 2023 | Form 483 | 483 Issued 10/04/2023 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists STAQ Pharma of Ohio, LLC, Columbus, OH (FEI number 3025336457), matched to this page by exact name, city and state. It lists 2 inspections: 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| May 16, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3025336457 | 1270348 |
| Oct 4, 2023 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3025336457 | 1219545 |
Form 483s FDA has published for this site
- Aug 19, 2026: Form 483 to STAQ Pharma of Ohio, LLC, published Sep 22, 2026. fda.gov
- May 16, 2025: Form 483 to STAQ Pharma of Ohio, LLC, published Jun 23, 2025. fda.gov
- Oct 4, 2023: Form 483 to STAQ Pharma of Ohio, LLC, published Jan 25, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 8 numbered observations in all, across 3 inspections ending Oct 4, 2023 to Aug 19, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 10, 2026 to Aug 19, 2026: 3 observations
- Firm on the cover
- STAQ Pharma of Ohio, LLC, 255 Phillipi Rd, Columbus, OH 43228-1307
- FEI number
- 3025336457
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 550 Main Street, Ste 49 30 Cincinnati, OH 45202
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically,
Your firm's visual inspection qualification procedure for sterile injectable drug products compounded and packaged in syringes is inadequate to ensure that visual inspectors are appropriately qualified to detect defects.
A. The visual inspection qualification process does not require operators to distinguish between critical and major defects and the acceptance criteria to pass qualification is <Redacted B4> of defective units identified, regardless of defect severity. For example, the current qualification <Redacted B4> for <Redacted B4> syringes contains <Redacted B4> defects, of which <Redacted B4> are critical defects and <Redacted B4> are major defects. During qualification, operators are not required to document the specific defect type identified, and qualification proctors determine only whether the rejected units contained an actual defect. ...
Observation 2
Batch production and control records do not include in-process results for each batch of drug product produced.
Specifically,
Actual light intensity values measured prior to starting visual inspection are not recorded in the production batch records; instead, the records document only whether the established light intensity acceptance criteria was met using a "Yes/No" check box. For example, for Succinylcholine Chloride 20 mg/mL, 10 mL in 10 mL syringe, Injection Batch 62116169A (batch size <Redacted B4> syringes, manufactured on <Redacted B4>, BUD 10/30/2026), light intensity was measured during visual inspection, however, the batch record only documented whether the light intensity met the established acceptance criteria.
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Specifically,
Media fills or aseptic process simulations performed do not closely simulate actual production conditions or represent all syringe configurations. In addition, operators were not qualified prior to the introduction of new gowning components to ensure that the gowning was donned appropriately.
A. Your firm's media fill program does not include worst-case conditions for all syringe sizes used in
sterile compounding operations. No media fill has been performed for the <Redacted B4> syringe s i ze <Reda cted B4> since 2024. Approximately, <Redacted B4> batches in <R edacted B4> syringes have bee n comp ounded a nd rel ease d since O ctober 2025. For e xample, Sodiu m Ch lor ide 9 mg/ mL, <Redac ted B4> in <Reda cted B4> s yringes , Inj ection Batch 621 6915 2A (batch si ze < Redacted B4> syr inges, BU D 12/08/2026) was compounded on <Redacted B4>
B. Your firm's media fill program does not adequately simulate actual aseptic production conditions. ...
Inspection May 6, 2025 to May 16, 2025: 3 observations
- Firm on the cover
- STAQ Pharma of Ohio, LLC, 255 Phillipi Rd, Columbus, OH 43228-1307
- FEI number
- 3025336457
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 550 Main Street, Ste 4930 Cincinnati, OH 45202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, you did not perform an investigation to identify the root cause(s) for critical defects observed during the 100% visual inspection and the subsequent Accepted Quality Limit (AQL) inspection process.
You observed particulate matter that you determine to be critical and major defects during the visual inspection of Dexmedetomidine Hydrochloride 4 mcg/mL, 5mL in a 5mL syringe, Lot <Redacted B4>. The initial 100% visual inspection identified 85 defects (74 critical, 9 major and 2 not classified). After this 100% visual inspection, followed by a failed AQL inspection which identified 1 critical defect. After you confirmed the AQL failure you did not initiate an investigation to determine the root cause of the critical defect. Instead, you performed a second 100% visual inspection for the same lot. The second 100% visual inspection identified 94 defects (87 critical and 7 major categories), which was more than the first 100% visual inspection. ...
Observation 2
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purpolied or represented to possess.
Specifically,
A The acceptance sampling inspection governed by procedure SOP-0052 "Sampling Plans" Rev 2, Effective Date 09 Feb 2024 does not clearly define reinspection parameters, fails to establish scientifically sound acceptance criteria following reinspection, or require lots that fail to meet initial Acceptable Quality Limits (AQL) to be rejected.
B -The 100% visual inspection program governed by procedure OH-SOP-0012 "Visual Inspection OH" Rev 5, Effective Date 26 Mar 2025 does not establish acceptance criteria for each defect categories ( critical, major, or minor defects), and does not require trending of the different defect categories.
C- The use of <Redacted B4> for inspecting colored vials is not established. Your firm produces methotrexate drug product that are dispensed in amber ( colored) vials. Additionally there is no documentation of under what <Redacted B4> the product is inspected. ...
Observation 3
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A) of the Federal Food, Drug, and Cosmetic Act (FD&CAct).
Specifically, your labels do not include the following information:
Subject to paragraph (B)(i), a list of active ingredient(s), identified by established name and the quantity or proportion of the active ingredient(s).
Examples of your drug product labels that do not contain this information include, but are not limited to:
• Phenylephrine HCl 100 mcg/5 mL • Succinylcholine Cl 100 mg/5 mL • Succinylcholine Cl 200 mg/10 mL
Inspection Sep 18, 2023 to Oct 4, 2023: 2 observations
- Firm on the cover
- STAQ Pharma of Ohio, LLC, 255 Phillipi Rd, Columbus, OH 43228-1307
- FEI number
- 3025336457
- Establishment type on the cover
- Outsourcing facility
- FDA district office on the cover
- 550 Main Street, Ste 4-930 Cincinnati, OH 45202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically,
Your executed media fill lots <Redacted B4>, and <Redacted B4> all performed in <Redacted B4> were compounded and then filled using a <Redacted B4> mL fill volume in <Redacted B4> mL syringe size configuration. This does not repliicate your actual commercial batch production configuration, of <Redacted B4> mL fill volume in 10mL syringes for Phenylephrine HCL (1000 mcg / 10 mL), lot <Redacted B4>, manufactured on <Redacted B4> Expiration date 12/24/2023. Your firm currently compounds no commercial product filled into <Redacted B4> mL syringes and only fills into 10 mL syringes. Batch size for media fill and commercial lots both yield approximately <Redacted B4> units; however, the total volume filled for media fill lots is approximately <Redacted B4> whereas commercial lots is approximately <Redacted B4>.
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
The location of your viable and nonviable particle sample collection points inside your ISO-5 <Redacted B4> Laminar Flow Hood in room <Redacted B4> is inadequate as they are situated directly adjacent to the HEPA air filter grate at the back of the hood. Samples collected evaluate only the air flowing immediately out of the HEPA filter, not air that is representative of the operational sterile filling area where <Redacted B4> aseptic filling manipulations are being conducted.
State board of pharmacy records
State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NSF 151 | Nonresident Outsourcing Facility | Staq Pharma Of Ohio Llc | Columbus, OH | Active |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0010095 | Outsourcing Facility-Distributor | STAQ Pharma of Ohio, LLC | COLUMBUS, OH | Active |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301013323 | Pharmacy | STAQ Pharma of Ohio, LLC | Columbus, OH | Active |
FDA’s 503B list
- STAQ Pharma of Ohio, LLC, Columbus, OH: last inspection Aug 19, 2026, Form 483 at that inspection: Yes, action FDA lists: Open.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.